NCT01987765View on ClinicalTrials.gov

Safety and Efficacy of Relestat Ophthalmic Solution 0.05% for Allergic Conjunctivitis in Korea

CompletedOBSERVATIONAL
Enrollment

847

Participants

Timeline

Start Date

January 31, 2009

Primary Completion Date

September 30, 2012

Study Completion Date

September 30, 2012

Conditions
Conjunctivitis, Allergic
Interventions
DRUG

Relestat Ophthalmic Solution 0.05%

Relestat Ophthalmic Solution 0.05% prescribed as local standard of care in clinical practice.

Trial Locations (1)

Unknown

Gangwon-do

Sponsors

Lead Sponsor

Allergan
All Listed Sponsors
lead

Allergan

INDUSTRY

NCT01987765 - Safety and Efficacy of Relestat Ophthalmic Solution 0.05% for Allergic Conjunctivitis in Korea | Biotech Hunter | Biotech Hunter